No Data
Retail Investors Who Hold 53% of Hainan Poly Pharm. Co., Ltd (SZSE:300630) Gained 14%, Insiders Profited as Well
Hainan Poly Pharm Estimates Less Than 15 Million Yuan in Asset Losses From Typhoon; Shares Up 6%
Puli Pharmaceuticals: Semi-Annual Report 2024
Puli Pharmaceuticals: 2024 Semi-Annual Report Summary
Hainan Poly Pharm (300630.SZ): Net loss of 56.81 million yuan in the first half of the year, turning into a loss from the previous year.
On August 28, Geelong Hui announced its semi-annual report, with revenue of 0.437 billion yuan, a year-on-year decrease of 6.99%, a net loss of 56.81 million yuan, a year-on-year switch to loss, a non-deductible net loss of 72.39 million yuan, a year-on-year switch to loss, and a basic earnings per share of -0.13 yuan.
There is a risk of diffusion! WHO has launched a global strategic preparedness, and monkeypox concept stocks have surged in response.
New variant appears.
Investors Holding Back On Hainan Poly Pharm. Co., Ltd (SZSE:300630)No Data
No Data
